Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
|ClinicalTrials.gov Identifier: NCT00467831|
Recruitment Status : Terminated (insufficient enrollment)
First Posted : May 1, 2007
Results First Posted : August 2, 2013
Last Update Posted : August 2, 2013
This study will examine whether five drugs (pravastatin, Losartan, Zileuton, N-acetylcysteine and erythromycin) used together can slow the course of pulmonary fibrosis (scarring of the lung tissue) in patients with Hermansky-Pudlak Syndrome (HPS). Patients with this disease have decreased skin color (albinism), bleeding problems, and sometimes colon problems. Two of the known types of Hermansky Pudlak syndrome, type 1 and type 4, are at high risk of pulmonary fibrosis between the ages of 30 and 50.
Patients 18 to 70 years of age who have Hermansky-Pudlak Syndrome with a serious loss of lung function due to pulmonary fibrosis may be eligible for this study.
Participants begin taking pravastatin on study day 2 and start a new drug every 3 days. Patients who experience no problems with the medicines return home and continue on the drugs for the next 2 years. They return to the NIH Clinical Center every 3 months for a medical history, physical examination, and blood, urine and lung function tests. CT and bone density scans are done every year. The study may continue for up to 3 years.
|Condition or disease||Intervention/treatment||Phase|
|Hermansky-Pudlak Syndrome (HPS) Pulmonary Fibrosis Oculocutaneous Albinism Platelet Storage Pool Deficiency Metabolic Disease||Drug: Losartan Drug: Zileuton Drug: N-Acetylcysteine Drug: Pravastatin Drug: Erythromycin||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome|
|Study Start Date :||April 2007|
|Primary Completion Date :||November 2012|
|Study Completion Date :||November 2012|
Experimental: Multi-Drug Regimen
Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
Losartan potassium tablet, 25 mg by mouth every night at bedtime.
Other Name: CozaarDrug: Zileuton
Zileuton tablet, 1200 mg by mouth twice daily.
Other Name: ZyfloDrug: N-Acetylcysteine
N-acetylcysteine solution, 600 mg by mouth three times daily.
Other Name: acetylcysteineDrug: Pravastatin
Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
Other Name: PravacholDrug: Erythromycin
Erythromycin tablet, 333 mg by mouth three times daily.
- Survival at 2 Years [ Time Frame: 24 months ]The number of subjects surviving after 24 months on study.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00467831
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Thomas Markello, M.D.||National Human Genome Research Institute (NHGRI)|